Pharmacokinetics

In vivo pharmacokinetics across rodent and non-rodent species, designed around the question rather than a standard protocol. Route and dose selection, sampling schedules and bioanalysis are set up together, so exposure data arrives ready to pair with efficacy.

ChemPartner has conducted 120-150 PK studies per week and served many pharmacokinetics (PK) clients.

  • AAALAC and OLAW accredited animal facilities with access to broad ranges of animal species
  • State-of-the-art instruments
  • Extensive experience in PK model development with comprehensive in vivo techniques such as surgical operation and animal care
  • Formulation support for in vivo studies including formulation screening, development, and formulation recommendation for various species and strains
  • PK/PD data analysis, modeling, and simulation
  • Regulatory filing support

 

Animal Species

  • Mouse, rat, guinea pig, rabbit, dog, monkey, and mini pig

 

Dose Route

  • Conventional administration routes: IV, PO (capsule & tablet, etc.), SC, IP, IM, topical administration
  • Special Clinical or Research Application: IV infusion, SC infusion, intranasal (IN), rectal, retro-orbital injection, intravitreal injection, intrathecal injection
  • Advanced methods: AZ pump, intracerebroventricular (ICV), intratracheal (IT)

 

Sampling

  • Venous: Tail vein, jugular vein, facial vein and submandibular
  • Cerebrospinal fluid (CSF): Cisternae magna puncture, spinal cord puncture
  • Bodily fluids/samples: Tear collection, lymph collection, urine collection, feces collection
  • In-life tissue biopsy: Adipose, muscle, liver, kidneys, etc.
  • Brain region-specific sampling
  • Intraocular region sampling

 

Comprehensive Surgical Techniques

  • Portal vein cannulation
  • Mesenteric lymph duct cannulation
  • Bile duct cannulation (mouse, rat, dog, and monkey)
  • Enteral administration (duodenum, jejunum, ileum, colon, rectum)
  • Terminal CSF collection (mice) and survival CSF collection (rat, mini pigs, dog, and monkey)

 

Biological Matrix

  • Blood, plasma, urine, tissue, CSF, brain, sciatic nerve, DRG, lymph node, bone marrow and all other tissues.

 

Pre-formulation Development

  • Physicochemical characterization

    • Polarized light microscopy
    • DSC &TGA
    • XRPD
    • DVS
    • PSD
    • logD, logP, pKa
    • Thermodynamic solubility
    • Solution/suspension stability
    • Solid state property
    • Dissolution test

  • Salt screening
  • Polymorph screening
  • Ball milling
  • Solid dispersion screening and spray drying

 

Formulation Development

  • Clear solution strategy for IV dosing
  • Suspension formulation strategy for chronic toxicity study
  • Simulated intestinal fluid (SIF) and simulated gastric fluid (SGF) dilution study for in vivo precipitation and super-saturation prediction
  • Advanced formulation approach (microsuspension, nanosuspension or solid dispersion)

START YOUR JOURNEY
Phase
Modality
Therapeutic Area